Weekly round-up: Infinitopes to Showcase Breakthroughs on Cancer Vaccine Development at SITC 2024: Insight into a double-blind, Phase I/IIa clinical trial

/in

Infinitopes, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimulating protective immune responses, on Friday announced that it will be presenting three posters on its pioneering cancer vaccine discovery and development, including one that has been recognised as a ‘top 100’ poster presentation, at the Society […]

Read more

Why ‘healthspan’ is a vital new concept in life science investing

/in

At the Optimum Strategic Communications’ 16th Annual Healthcare Investor Conference, held on Thursday 10th October 2024 at The King’s Fund, London, Dr Mehmood Khan, CEO of the Hevolution Foundation, spoke to Clive Cookson, Senior Science Writer at the Financial Times, about investing in “healthspan”. What is “healthspan”? Unlike “lifespan” it isn’t an everyday term. Yet […]

Read more

Weekly round-up: Strong media coverage for radiopharmaceutical company Ariceum Therapeutics after early success in NHS brain tumour trial

/in

Remarkable results from the start of a trial testing Ariceum Therapeutics’ experimental radiopharmaceutical drug ATT001 in patients with recurrent glioblastoma brain cancer generated strong coverage in the UK’s national media this week. Meanwhile Ariceum’s Chief Operating Officer Greg Mullen featured in an Optimum TV episode, where he explained the highly targeted radiopharmaceutical approach, called Auger […]

Read more

This week’s hot topic: Birth rates are collapsing – can IVF help?

/in

By Stephen Adams  Birth rates are collapsing.  This week, it was the turn of England and Wales’s Office for National Statistics (ONS) to report that the fertility rate has dropped to just 1.44 children per woman – the lowest rate since records began in 1938 (1). The replacement rate is 2.08.  This isn’t unique. Birth […]

Read more

This week’s hot topic: Why Pharma will have to play the long game on Alzheimer’s drugs

/in

By Stephen Adams, Optimum Strategic Communications Few people expected England and Wales’s drugs spending watchdog, the National Institute for Health and Care Excellence (“NICE”), to approve Eli Lilly’s new dementia drug donanemab for use on the NHS last week.  At a reputed annual cost of at least £60,000 a year, including the care bill, it […]

Read more
© Optimum Strategic Communications.